​

NeuroPace (NPCE) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

NPCE Stock Forecast

NeuroPace (NPCE) stock forecast, based on 7 Wall Street analysts, predicts a 12-month average price target of $12.88, with a high of $20.00 and a low of $5.50. This represents a 23.49% increase from the last price of $10.43.

$5 $8 $11 $14 $17 $20 High: $20 Avg: $12.88 Low: $5.5 Last Closed Price: $10.43

NPCE Stock Rating

NeuroPace stock's rating consensus is Buy, based on 7 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 7 Buy (100.00%), 0 Hold (0.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 7 0 7 Strong Sell Sell Hold Buy Strong Buy

NPCE Price Target Upside V Benchmarks

TypeNameUpside
StockNeuroPace23.49%
SectorHealthcare Stocks 33.91%
IndustryMedical Device Stocks20.97%

Price Target Trends

1M3M12M
# Anlaysts--2
Avg Price Target--$17.50
Last Closing Price$10.43$10.43$10.43
Upside/Downside--67.79%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Apr, 2516---7
Mar, 2516---7
Feb, 2516---7
Jan, 2516---7
Dec, 2415---6
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Aug 14, 2024Vik ChopraWells Fargo$15.00$7.28106.04%43.82%
May 23, 2024Frank TakkinenLake Street$20.00$7.99150.31%91.75%
Mar 14, 2024Larry BiegelsenWells Fargo$20.00$13.6346.74%91.75%
Nov 10, 2023Ross OsbornCantor Fitzgerald$11.00$7.8540.13%5.47%
Jul 15, 2022Morgan Stanley$5.50$5.74-4.18%-47.27%
May 13, 2022Morgan Stanley$6.00$5.960.67%-42.47%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Aug 14, 2024Wells FargoOverweightOverweighthold
May 29, 2024Wells FargoOverweightOverweighthold
Mar 14, 2024Wells FargoBuyOverweightupgrade
Feb 22, 2024Wells FargoBuyBuyhold
Jan 30, 2024Lake StreetUnderperformUnderperformhold
Dec 27, 2023Wells FargoBuyBuyhold
Feb 22, 2023Piper SandlerNeutralinitialise
Jul 15, 2022Morgan StanleyUnderweightUnderweighthold
May 13, 2022Morgan StanleyUnderweightUnderweighthold

Financial Forecast

EPS Forecast

Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-1.56$-2.17$-1.27$-0.93----
Avg Forecast$-1.88$-1.97$-1.36$-0.99$-0.89$-0.64$-0.51$0.01
High Forecast$-1.83$-1.91$-1.30$-0.96$-0.78$-0.40$-0.50$0.01
Low Forecast$-1.91$-2.02$-1.41$-1.01$-1.02$-0.89$-0.53$0.01
Surprise %-17.02%10.15%-6.62%-6.06%----

Revenue Forecast

$0 $50M $100M $150M $200M $250M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$45.18M$45.52M$65.42M$79.91M----
Avg Forecast$44.92M$45.21M$64.48M$79.44M$92.39M$109.93M$155.68M$199.09M
High Forecast$45.53M$46.07M$66.03M$81.36M$93.73M$109.95M$159.44M$203.89M
Low Forecast$44.00M$44.12M$63.18M$77.84M$91.05M$109.90M$152.54M$195.07M
Surprise %0.59%0.68%1.46%0.59%----

Net Income Forecast

$-55M $-43M $-31M $-19M $-7M $5M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-38.11M$-53.37M$-32.96M-----
Avg Forecast$-48.63M$-50.86M$-35.07M$-25.47M$-23.32M$-20.41M$-13.22M$258.52K
High Forecast$-47.33M$-49.26M$-33.65M$-24.71M$-20.25M$-10.33M$-12.84M$266.63K
Low Forecast$-49.48M$-52.12M$-36.49M$-26.24M$-26.40M$-22.98M$-13.60M$251.74K
Surprise %-21.63%4.93%-6.03%-----

NPCE Forecast FAQ

Is NeuroPace stock a buy?

NeuroPace stock has a consensus rating of Buy, based on 7 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 7 Buy, 0 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that NeuroPace is a favorable investment for most analysts.

What is NeuroPace's price target?

NeuroPace's price target, set by 7 Wall Street analysts, averages $12.88 over the next 12 months. The price target range spans from $5.5 at the low end to $20 at the high end, suggesting a potential 23.49% change from the previous closing price of $10.43.

How does NeuroPace stock forecast compare to its benchmarks?

NeuroPace's stock forecast shows a 23.49% upside, underperforming the average forecast for the healthcare stocks sector (33.91%) and outperforming the medical device stocks industry (20.97%).

What is the breakdown of analyst ratings for NeuroPace over the past three months?

  • April 2025: 14.29% Strong Buy, 85.71% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • March 2025: 14.29% Strong Buy, 85.71% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • February 2025: 14.29% Strong Buy, 85.71% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is NeuroPace’s EPS forecast?

NeuroPace's average annual EPS forecast for its fiscal year ending in December 2025 is $-0.89, marking a -4.30% decrease from the reported $-0.93 in 2024. Estimates for the following years are $-0.64 in 2026, $-0.51 in 2027, and $0.01 in 2028.

What is NeuroPace’s revenue forecast?

NeuroPace's average annual revenue forecast for its fiscal year ending in December 2025 is $92.39M, reflecting a 15.63% increase from the reported $79.91M in 2024. The forecast for 2026 is $109.93M, followed by $155.68M for 2027, and $199.09M for 2028.

What is NeuroPace’s net income forecast?

NeuroPace's net income forecast for the fiscal year ending in December 2025 stands at $-23.323M, representing a 0% decrease from the reported $0 in 2024. Projections indicate $-20.408M in 2026, $-13.218M in 2027, and $258.52K in 2028.